

Enrico Franceschi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2075338/publications.pdf>

Version: 2024-02-01

168
papers

7,381
citations

81839

39
h-index

58549

82
g-index

181
all docs

181
docs citations

181
times ranked

8327
citing authors

#	ARTICLE	IF	CITATIONS
1	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. <i>New England Journal of Medicine</i> , 2017, 376, 1027-1037.	13.9	810
2	<i>MGMT</i> Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients. <i>Journal of Clinical Oncology</i> , 2008, 26, 2192-2197.	0.8	760
3	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	5.1	582
4	Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With <i>MGMT</i> Promoter Methylation Status. <i>Journal of Clinical Oncology</i> , 2009, 27, 1275-1279.	0.8	311
5	Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. <i>Neuro-Oncology</i> , 2008, 10, 361-367.	0.6	233
6	High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. <i>Cancer</i> , 2005, 103, 2344-2348.	2.0	223
7	Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). <i>British Journal of Cancer</i> , 2006, 95, 1155-1160.	2.9	221
8	Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma. <i>Cancer</i> , 2009, 115, 3512-3518.	2.0	207
9	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>British Journal of Cancer</i> , 2007, 96, 1047-1051.	2.9	179
10	Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 4746-4753.	0.8	171
11	Glioblastoma in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 139-152.	2.0	156
12	Temozolomide as salvage treatment in primary brain lymphomas. <i>British Journal of Cancer</i> , 2007, 96, 864-867.	2.9	135
13	Long-term results of a prospective study on the treatment of medulloblastoma in adults. <i>Cancer</i> , 2007, 110, 2035-2041.	2.0	126
14	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 684-693.	0.6	126
15	Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments. <i>Clinical Cancer Research</i> , 2008, 14, 957-960.	3.2	125
16	Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. <i>European Journal of Cancer</i> , 2004, 40, 1682-1688.	1.3	118
17	O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. <i>Neuro-Oncology</i> , 2010, 12, 283-288.	0.6	110
18	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 769-75.	1.1	89

#	ARTICLE	IF	CITATIONS
19	Salvage temozolomide for prior temozolomide responders. <i>Cancer</i> , 2005, 104, 2473-2476.	2.0	79
20	Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 89, 179-185.	1.4	79
21	Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial. <i>European Journal of Cancer</i> , 2013, 49, 3609-3615.	1.3	76
22	A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. <i>Cancer</i> , 2005, 104, 143-148.	2.0	75
23	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1304-1312.	0.6	71
24	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology</i> , The, 2020, 21, e317-e329.	5.1	69
25	Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 599-609.	1.4	66
26	Practical Management of Bevacizumab-Related Toxicities in Glioblastoma. <i>Oncologist</i> , 2015, 20, 166-175.	1.9	66
27	Role of <i>MGMT</i> Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. <i>Oncologist</i> , 2017, 22, 432-437.	1.9	61
28	EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 1503-1510.	0.6	58
29	Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. <i>British Journal of Cancer</i> , 2004, 90, 36-40.	2.9	56
30	Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 165-179.	2.0	56
31	EANOâ€œEURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology</i> , The, 2019, 20, e715-e728.	5.1	56
32	Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. <i>CNS Oncology</i> , 2021, 10, CNS72.	1.2	54
33	Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. <i>British Journal of Cancer</i> , 2004, 91, 1038-1044.	2.9	51
34	Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences. <i>Current Treatment Options in Oncology</i> , 2016, 17, 49.	1.3	48
35	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019, 24, 521-528.	1.9	47
36	Sex-specific clinicopathological significance of novel (Frizzled-7) and established (<i>MGMT</i> , <i>IDH1</i>) biomarkers in glioblastoma. <i>Oncotarget</i> , 2016, 7, 55169-55180.	0.8	45

#	ARTICLE	IF	CITATIONS
37	Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and Handling Strategies. <i>Oncologist</i> , 2010, 15, 683-694.	1.9	43
38	New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 348-359.	2.0	43
39	Nitrosoureas in the Management of Malignant Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 13.	2.0	43
40	The effect of re-operation on survival in patients with recurrent glioblastoma. <i>Anticancer Research</i> , 2015, 35, 1743-8.	0.5	42
41	Is protracted low-dose temozolomide feasible in glioma patients?. <i>Neurology</i> , 2006, 66, 427-429.	1.5	41
42	Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?. <i>Journal of Neuro-Oncology</i> , 2016, 128, 235-240.	1.4	40
43	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. <i>Oncologist</i> , 2021, 26, 865-878.	1.9	39
44	The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power. <i>World Neurosurgery</i> , 2018, 112, e342-e347.	0.7	36
45	EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1429-1435.	1.1	35
46	Prognostic factors for anaplastic astrocytomas. <i>Journal of Neuro-Oncology</i> , 2007, 81, 295-303.	1.4	33
47	Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapeutic agents changed the clinical outcome?. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, 212-221.	2.0	33
48	Treatment options for recurrent glioblastoma: pitfalls and future trends. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 613-619.	1.1	33
49	Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. <i>BMC Cancer</i> , 2010, 10, 48.	1.1	33
50	Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis. <i>Journal of Neuro-Oncology</i> , 2005, 73, 261-264.	1.4	32
51	Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 115-120.	1.1	31
52	Second surgery for recurrent glioblastoma: advantages and pitfalls. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 583-587.	1.1	29
53	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROC) <i>Tj ETQq1s1 0.784314 rgB</i>	1.1	29
54	Patient outcomes following second surgery for recurrent glioblastoma. <i>Future Oncology</i> , 2016, 12, 1039-1044.	1.1	25

#	ARTICLE	IF	CITATIONS
55	Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. <i>European Journal of Cancer</i> , 2020, 137, 10-17.	1.3	25
56	Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. <i>CNS Drugs</i> , 2017, 31, 675-684.	2.7	24
57	Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?. <i>Neuro-Oncology Practice</i> , 2014, 1, 166-171.	1.0	23
58	Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. <i>Journal of Neuro-Oncology</i> , 2016, 128, 157-162.	1.4	23
59	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 785-795.	1.1	23
60	Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration. <i>Magnetic Resonance Imaging</i> , 2003, 21, 1003-1007.	1.0	21
61	Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma. <i>European Journal of Cancer</i> , 2012, 48, 896-903.	1.3	20
62	Defining EGFR amplification status for clinical trial inclusion. <i>Neuro-Oncology</i> , 2019, 21, 1263-1272.	0.6	20
63	Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma (MPA): Clinical and translational results of a phase II randomized trial (NCT00967603).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4017-4017.	0.8	20
64	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 457-473.	1.6	19
65	Survival outcomes in glioma patients with noncanonical IDH mutations: Beyond diagnostic improvements.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2028-2028.	0.8	19
66	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. <i>Neuro-Oncology</i> , 2022, 24, 1726-1735.	0.6	18
67	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022, 82, 491-510.	4.9	18
68	Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. <i>Journal of Neuro-Oncology</i> , 2017, 135, 245-254.	1.4	17
69	The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?. <i>Future Oncology</i> , 2018, 14, 1559-1567.	1.1	17
70	Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19. <i>Immunotherapy</i> , 2020, 12, 1111-1114.	1.0	17
71	Medulloblastomas in adults. <i>Current Opinion in Neurology</i> , 2011, 24, 626-632.	1.8	16
72	Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. <i>Journal of Clinical Pathology</i> , 2015, 68, 859-869.	1.0	16

#	ARTICLE	IF	CITATIONS
73	Immunotherapy in head and neck cancer: evidence and perspectives. <i>Immunotherapy</i> , 2017, 9, 1351-1358.	1.0	16
74	Molecular alterations in pancreatic tumors. <i>World Journal of Gastroenterology</i> , 2021, 27, 2710-2726.	1.4	16
75	Glioblastoma: Emerging Treatments and Novel Trial Designs. <i>Cancers</i> , 2021, 13, 3750.	1.7	16
76	Chimeric antigen receptor macrophage for glioblastoma immunotherapy: the way forward. <i>Immunotherapy</i> , 2021, 13, 879-883.	1.0	16
77	Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: a long term study. <i>BMC Cancer</i> , 2020, 20, 755.	1.1	15
78	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. <i>Diagnostics</i> , 2021, 11, 342.	1.3	15
79	Shedding Light on Adult Medulloblastoma: Current Management and Opportunities for Advances. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e82-e87.	1.8	14
80	Rare Primary Central Nervous System Tumors in Adults: An Overview. <i>Frontiers in Oncology</i> , 2020, 10, 996.	1.3	14
81	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. <i>Future Oncology</i> , 2020, 16, 1433-1439.	1.1	14
82	Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors. <i>Journal of Neuro-Oncology</i> , 2006, 79, 299-305.	1.4	13
83	Predictive markers of immune response in glioblastoma: hopes and facts. <i>Future Oncology</i> , 2020, 16, 1053-1063.	1.1	13
84	Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 179-184.	1.1	12
85	Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?. <i>Journal of Neuro-Oncology</i> , 2018, 139, 383-388.	1.4	12
86	Temozolomide rechallenge in recurrent glioblastoma: when is it useful?. <i>Future Oncology</i> , 2018, 14, 1063-1069.	1.1	11
87	Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. <i>Diagnostics</i> , 2021, 11, 1852.	1.3	11
88	Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. <i>Advances in Therapy</i> , 2022, 39, 165-177.	1.3	11
89	Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. <i>Future Oncology</i> , 2013, 9, 1653-1664.	1.1	10
90	Resistance to antiangiogenic therapies. <i>Future Oncology</i> , 2014, 10, 1417-1425.	1.1	10

#	ARTICLE	IF	CITATIONS
91	Post progression survival in glioblastoma: where are we?. Journal of Neuro-Oncology, 2015, 121, 399-404.	1.4	10
92	The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria. Oncology and Therapy, 2018, 6, 105-108.	1.0	10
93	Impact of deparatuzumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. European Journal of Cancer, 2021, 147, 1-12.	1.3	10
94	Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux-M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).. Journal of Clinical Oncology, 2018, 36, 2023-2023.	0.8	10
95	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. Oncotarget, 2017, 8, 55575-55581.	0.8	10
96	Bevacizumab in recurrent glioblastoma: open issues. Future Oncology, 2015, 11, 2655-2665.	1.1	9
97	Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1105GGT) in brain tumors of a cohort of Italian patients. Scientific Reports, 2018, 8, 4459.	1.6	9
98	EGFR mutations are associated with response to deparatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. Neuro-Oncology Advances, 2020, 2, vdz051.	0.4	9
99	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. Immunotherapy, 2021, 13, 419-432.	1.0	9
100	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. Expert Review of Anticancer Therapy, 2021, 21, 1333-1353.	1.1	9
101	Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance. Frontiers in Oncology, 2022, 12, 852950.	1.3	9
102	Primary Brain Tumors in the Elderly Population. Current Treatment Options in Neurology, 2011, 13, 427-435.	0.7	8
103	Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?. Expert Review of Anticancer Therapy, 2011, 11, 657-660.	1.1	8
104	A Randomized Controlled Trial of Tong Len Meditation Practice in Cancer Patients: Evaluation of a Distant Psychological Healing Effect. Explore: the Journal of Science and Healing, 2016, 12, 42-49.	0.4	8
105	Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23. Cancers, 2021, 13, 3451.	1.7	8
106	Association between response to primary treatments and MGMT status in glioblastoma. Expert Review of Anticancer Therapy, 2008, 8, 1781-1786.	1.1	7
107	Brain metastases from non-small-cell lung cancer: is there room for improvement?. Expert Review of Anticancer Therapy, 2012, 12, 421-423.	1.1	7
108	Glioneuronal tumors: clinicopathological findings and treatment options. Future Neurology, 2020, 15, .	0.9	7

#	ARTICLE	IF	CITATIONS
109	The <i>EGFRvIII</i> transcriptome in glioblastoma: A meta-omics analysis. <i>Neuro-Oncology</i> , 2022, 24, 429-441.	0.6	7
110	Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. <i>European Journal of Cancer</i> , 2021, 145, 171-178.	1.3	7
111	Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1185-1194.	1.2	7
112	Neuro-Oncology During the COVID-19 Outbreak: A Hopeful Perspective at the End of the Italian Crisis. <i>Frontiers in Medicine</i> , 2020, 7, 594610.	1.2	7
113	Tumor-Associated Microenvironment of Adult Gliomas: A Review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
114	New Agents and New End Points for Recurrent Gliomas. <i>Journal of Clinical Oncology</i> , 2011, 29, e245-e246.	0.8	6
115	The role of systemic and targeted therapies in brain metastases. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 93-103.	1.1	6
116	miR-196B-5P and miR-200B-3P Are Differentially Expressed in Medulloblastomas of Adults and Children. <i>Diagnostics</i> , 2020, 10, 265.	1.3	6
117	IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. <i>Pathology Research and Practice</i> , 2021, 221, 153445.	1.0	6
118	Low grade glioma patients with IDH mutation and 1p19q codeletion: To treat or not to treat?. <i>Journal of Clinical Oncology</i> , 2017, 35, 2017-2017.	0.8	6
119	Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?. <i>Cancers</i> , 2022, 14, 333.	1.7	6
120	Bevacizumab in brain tumors: ready for primetime?. <i>Future Oncology</i> , 2009, 5, 1183-1184.	1.1	5
121	Genetic variation in pediatric and adult brain tumors. <i>Nature Reviews Neurology</i> , 2010, 6, 653-654.	4.9	5
122	The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials. <i>CNS Oncology</i> , 2015, 4, 117-119.	1.2	5
123	Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas. <i>Future Oncology</i> , 2019, 15, 2595-2601.	1.1	5
124	The clinical and prognostic role of ALK in glioblastoma. <i>Pathology Research and Practice</i> , 2021, 221, 153447.	1.0	5
125	BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma. <i>Immunotherapy</i> , 2022, 14, 169-172.	1.0	5
126	Machine learning in neuro-oncology: toward novel development fields. <i>Journal of Neuro-Oncology</i> , 2022, 159, 333-346.	1.4	5

#	ARTICLE	IF	CITATIONS
127	Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04604.	0.2	4
128	Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1265-1272.	1.1	4
129	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 2047-2047.	0.8	4
130	Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. <i>Diagnostics</i> , 2022, 12, 1058.	1.3	4
131	End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1713-1717.	1.1	3
132	Cytologically confirmed splenic metastases in breast cancer. <i>Future Oncology</i> , 2012, 8, 1495-1500.	1.1	3
133	The burden of oncology promises not kept in glioblastoma. <i>Future Neurology</i> , 2018, 13, 1-4.	0.9	3
134	Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable?. <i>Child's Nervous System</i> , 2019, 35, 2279-2287.	0.6	3
135	Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?. <i>Oncologist</i> , 2019, 24, 664-670.	1.9	3
136	Immunotherapy in elderly patients: should we stay or should we go?. <i>Future Oncology</i> , 2020, 16, 973-974.	1.1	3
137	Burnout in medical oncology during the COVID-19 pandemic. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 351-353.	1.1	3
138	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?. <i>Immunotherapy</i> , 0, , .	1.0	3
139	HER-2 Inhibitors: Clinical Results. <i>Tumori</i> , 2002, 1, S3-S4.	0.6	2
140	New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1129-1131.	1.1	2
141	Adjuvant temozolomide: how long and how much?. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 663-665.	1.1	2
142	Gangliogliomas: recent advances in classification and treatment. <i>Future Neurology</i> , 2010, 5, 557-568.	0.9	2
143	The metastatic process: a kaleidoscope of concepts. <i>Future Oncology</i> , 2014, 10, 697-698.	1.1	2
144	Second-Line Chemotherapy in Recurrent Glioblastoma - Still Controversial. <i>Oncology Research and Treatment</i> , 2015, 38, 345-346.	0.8	2

#	ARTICLE	IF	CITATIONS
145	Immune-checkpoint inhibitors in pituitary malignancies. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	2
146	Is There a Role for Surgical Resection of Multifocal Glioblastoma? A Retrospective Analysis of 100 Patients. <i>Neurosurgery</i> , 2021, 89, 1042-1051.	0.6	2
147	Anaplastic gliomas at first recurrence: Outcome analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2061-2061.	0.8	2
148	Trastuzumab in CNS progressive metastatic breast cancer. <i>Future Oncology</i> , 2007, 3, 367-369.	1.1	1
149	Adjuvant therapy in glioblastomas: false steps and real advances. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 607-608.	1.1	1
150	The role of gender in glioblastoma: does it matter?. <i>Future Neurology</i> , 2016, 11, 197-199.	0.9	1
151	Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. <i>Tumori</i> , 2021, , 030089162110172.	0.6	1
152	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. <i>Clinical Drug Investigation</i> , 2021, 41, 757-773.	1.1	1
153	Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7600-7600.	0.8	1
154	Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2047-2047.	0.8	1
155	Adjuvant chemotherapy to improve survival in average-risk adult medulloblastoma patients: Long-term results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2037-2037.	0.8	1
156	Challenges and progress in the treatment of adult medulloblastomas. <i>Future Oncology</i> , 2007, 3, 115-117.	1.1	0
157	Metastatic process: the seed and the soil from bench to bedside. <i>Future Oncology</i> , 2013, 9, 1597-1598.	1.1	0
158	Medulloblastomas. , 2011, , 415-433.		0
159	Natural history of glioblastoma in the modern era: Longitudinal results from a large prospective Italian register.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2057-2057.	0.8	0
160	Final results from a large prospective Italian population study on glioblastoma and correlations with MGMT status: The Project of Emilia-Romagna Region in Neuro-oncology (PERNO).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2048-2048.	0.8	0
161	A large prospective Italian population study (Project of Emilia-Romagna Region in Neuro-Oncology;) Tj ETQq1 1 0.784314 rgBT /Overl methylation status in the elderly population.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2021-2021.	0.8	0
162	Association of high volume center with survival for glioblastoma patients: Results from a prospective population-based registry (PERNO).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2048-2048.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Can average-risk medulloblastoma adult patients be treated with radiotherapy and plus chemotherapy?. Journal of Clinical Oncology, 2014, 32, 2022-2022.	0.8	0
164	The role of clinical characteristics and molecular biomarkers in low grade gliomas (LGG): A GICNO study.. Journal of Clinical Oncology, 2016, 34, 2032-2032.	0.8	0
165	Concordance between RTOG and EORTC risk factors in low grade gliomas: Who will remain standing in the ring at bellâ€™s sound?. Journal of Clinical Oncology, 2018, 36, 2040-2040.	0.8	0
166	Third-line therapy in glioblastoma: Analysis of a single centre database.. Journal of Clinical Oncology, 2018, 36, e14057-e14057.	0.8	0
167	Effect of grade on survival in IDH-mutant grade II and grade III gliomas.. Journal of Clinical Oncology, 2019, 37, 2036-2036.	0.8	0
168	IDH1 polymorphism G105G (rs11554137) as a prognostic factor in gliomas.. Journal of Clinical Oncology, 2019, 37, e14734-e14734.	0.8	0